Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RenaKare is a veterinary oral potassium supplement product developed and marketed by Neogen for correction of potassium-deficient states in cats and dogs. Its active ingredient is potassium gluconate, a **small molecule** electrolyte replacement that supplies potassium to restore serum and intracellular potassium levels, thereby supporting normal neuromuscular function, cellular electrophysiology, and overall electrolyte balance rather than acting through a discrete pharmacologic receptor target. It is used particularly in veterinary patients with hypokalemia associated with chronic kidney disease, vomiting, or diarrhea, and is available in multiple oral formulations including tablets, powder, and gel. The product is intended for use by or on the order of a licensed veterinarian and is marketed as an animal health product rather than as an FDA-approved human pharmaceutical.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on RenaKare.